Cited by 90Amyotrophic Lateral Sclerosis ResearchHeat shock proteins researchGenetic Neurodegenerative Diseases

Failure of protein quality control in amyotrophic lateral sclerosis

Open access
Kabashi, Edor, Durham, Heather D.·2006·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Abstract

The protein chaperoning and ubiquitin-proteasome systems perform many homeostatic functions within cells involving protein folding, transport and degradation. Of paramount importance is ridding cells of mutant or post-translationally modified proteins that otherwise tend to aggregate into insoluble complexes and form inclusions. Such inclusions are characteristic of many neurodegenerative diseases and implicate protein misfolding and aggregation as common aspects of pathogenesis. In the most common familial form of ALS, mutations in SOD1 promote misfolding of the protein and target it for degradation by proteasomes. Although proteasomes can degrade the mutant proteins efficiently, altered solubility and aggregation of mutant SOD1 are features of the disease and occur most prominently in the most vulnerable cells and tissues. Indeed, lumbar spinal cord of mutant SOD1 transgenic mice show early reduction in their capacity for protein chaperoning and proteasome-mediated hydrolysis of substrates, and motor neurons are particularly vulnerable to aggregation of mutant SOD1. A high threshold for upregulating key pathways in response to the stress of added substrate load may contribute to this vulnerability. The broad spectrum neuroprotective capability and efficacy of some chaperone-based therapies in preclinical models makes these pathways attractive as targets for therapy in ALS, as well as other neurodegenerative diseases. A better understanding of the mechanisms governing the regulation of protein chaperones and UPS components would facilitate development of treatments that upregulate these pathways in a coordinated manner in neural tissue without long term toxicity.

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2006.06.006

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In neurological disease and aging, modified proteins are the histopathological hallmarks of a number of diseases, such as SOD1 in amyotrophic lateral sclerosis (ALS), and a class of diseases long referred to as the proteinopathies, including tauopathies in Alzheimer's disease and inclusions of amyloid beta, alpha-synuclein in Parkinson's and multiple secondary ubiquitinopathies.

    “In neurological disease and aging, modified proteins are the histopathological hallmarks of a number of diseases, such as SOD1 in amyotrophic lateral sclerosis (ALS) 56,57 , and a class of diseases long referred to as the proteinopathies 57 , including tauopathies in Alzheimer's disease 58 and inclusions of amyloidβ 59 , α -synuclein in Parkinson's 60,61 and multiple secondary ubiquitinopathies”

    From How many human proteoforms are there? (2018) · cites this paper as [63]

Cites

Flagged first, then by citations

1 of the 151 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kabashi, E., & Durham, H. D.
Affiliations
Montreal Neurological Institute and Hospital (CA)
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2006-11
Volume
1762
Issue
11-12
Pages
1038-1050
ISSN
0925-4439 (ISSN-L)
OpenAlex
W2117212431
Cited by
90
References
151
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 6 · 2015: 2 · 2014: 3 · 2013: 5 · 2012: 7
FWCI
1.36
Type
journal article
Language
en
Open access
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
amyotrophic lateral sclerosis, protein quality control, molecular chaperones, ubiquitin-proteasome system, SOD1 mutations, protein misfolding, protein aggregation, motor neurons, proteasomal degradation, transgenic mouse model
MeSH terms
Superoxide Dismutase-1, Amyotrophic Lateral Sclerosis, Animals, Humans, Lumbar Vertebrae, Mice, Transgenic, Models, Biological, Neurons, Superoxide Dismutase, Signal Transduction, Protein Folding, Oxidative Stress, Molecular Chaperones, Ubiquitin, Proteasome Endopeptidase Complex, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review